Gold Price Holds Near $4,400 as Hormuz Risks and CPI Drive Markets 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Dollar Steady as Markets Await U.S. Inflation Data 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
US Judge Dismisses Gautam Adani Criminal Charges 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
U.S. Stock Futures Flat Ahead of July CPI Data 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
